About the Company
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AGLE News
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones
Sept. 5, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the ...
Aeglea BioTherapeutics Announces Reverse Stock Split
WALTHAM, Mass., Sept. 7, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to ...
Aeglea Bio Therapeutics Inc (AGLE)
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) announced new positive phase I/II data for pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D), a rare genetic ...
Aeglea BioTherapeutics to Participate in Upcoming September Conference
WALTHAM, Mass., Sept. 14, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to ...
Aeglea BioTherapeutics Appoints Scott Burrows As Chief Financial Officer
(RTTNews) - Aeglea BioTherapeutics, Inc. (AGLE), a company focused on the treatment of inflammatory bowel disease, said on Tuesday that it has appointed, Scott Burrows, as Chief Financial Officer.
Aeglea BioTherapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Aeglea BioTherapeutics Announces Reverse Stock Split
WALTHAM, Mass., Sept. 7, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to ...
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones
Sept. 5, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the ...
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones
About Aeglea BioTherapeutics In June 2023, Aeglea completed the asset acquisition of Spyre Therapeutics, Inc. and shifted its disease focus to IBD. Aeglea is advancing a pipeline of antibody ...
Aeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Announces Reverse Stock Split
WALTHAM, Mass., Sept. 7, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to ...
Aeglea BioTherapeutics Announces Reverse Stock Split
WALTHAM, Mass., Sept. 7, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to ...
Loading the latest forecasts...